Clincosm LogoSign in Get a demo

metastatic nasopharyngeal carcinoma

Showing 1 - 9 of 9
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8 Trial

Not yet recruiting
  • Metastatic Nasopharyngeal Carcinoma
  • +2 more
  • Nivolumab
  • +5 more
  • (no location specified)
Aug 21, 2023

Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8 Trial

Not yet recruiting
  • Metastatic Nasopharyngeal Carcinoma
  • +2 more
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Jun 13, 2023

Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemo Effect Trial in Guangzhou (PD-1 Immune Checkpoint

Active, not recruiting
  • Recurrent Nasopharyngeal Carcinoma
  • +2 more
  • PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab
  • Guangzhou, Guangdong, China
    Yanqun Xiang
Sep 5, 2022

Metastatic Nasopharyngeal Carcinoma Trial (Capecitabine plus toripalimab)

Not yet recruiting
  • Metastatic Nasopharyngeal Carcinoma
  • Capecitabine plus toripalimab
  • (no location specified)
Jul 30, 2022

Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Metastatic Nasopharyngeal

Active, not recruiting
  • Metastatic Nasopharyngeal Carcinoma
  • +10 more
  • Birmingham, Alabama
  • +324 more
Jun 28, 2022

Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma Trial in Singapore (TAS-102)

Recruiting
  • Metastatic Nasopharyngeal Carcinoma
  • Recurrent Nasopharyngeal Carcinoma
  • Singapore, Singapore
    National University Hospital
Nov 11, 2020

Epstein-Barr Virus Positive, Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma Trial (Durvalumab,

Withdrawn
  • Epstein-Barr Virus Positive
  • +6 more
  • (no location specified)
Oct 22, 2020

Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma Trial in Guangzhou (Apatinib

Unknown status
  • Nasopharyngeal Carcinoma
  • +5 more
  • Apatinib plus Camrelizumab
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 7, 2020

Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma Trial in Beijing (Anlotinib plus gemcitabine/cisplatin)

Recruiting
  • Recurrent Nasopharyngeal Carcinoma
  • Metastatic Nasopharyngeal Carcinoma
  • Anlotinib plus gemcitabine/cisplatin
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospitial,Chinese Academy of Medic
Sep 17, 2018